The Role of Peptide YY (PYY)in Inhibiting Food Intake.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-03-31

Study Completion Date

2005-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

12 obese subjects will receive peripheral administration of placebo and 4 escalating doses of PYY1-36 and another 12 obese subjects will receive peripheral administration of placebo and 4 escalating doses PYY3-36 on 5 different test days within one week. The patients will be tested in a single blinded dose escalating protocol. Measurements of appetite, ad libitum energy intake, blood pressure and blood sampling will be performed during the test day.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Role of Peptide YY (PYY)Infusions in Inhibiting Food Intake.

NCT00259246

Obesity

COMPLETED NA

Exogenous Ketones and Appetite

NCT06327464

Appetite Obesity Ketones +1 more

RECRUITING NA

Glycogen and Appetite

NCT05417659

Energy Intake

COMPLETED NA

Effect of Medium Chain Triglyceride Consumption on Appetite

NCT01952977

Obesity

COMPLETED NA

Effect of Feeding Status on Appetite and Eating Behaviour.

NCT07257692

Healthy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

peripheral Peptide YY administration

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Normal weight (BMI: 18-23 kg/m2) or 12 overweight/obese (BMI: 27-40 kg/m2)
* Body weight fluctuations \< 5 kg over the past 2 months.
* Blood pressure normal to mildly hypertensive(\<159/99 mm Hg)
* Non-elite athletes and not planning to change physical activity during the study.

Exclusion Criteria

* Any physiological or psychological illnesses that could influence the study results.
* Regular use of medicine.
* Smoking defined as \<1 cigarette per day.
* Substance abuse or dependence.
* Blood donation within the past 3 months before entering the study.
* Drinking \>21 alcoholic units/week.
* Food allergies.
* Special diets (e.g. vegetarian) or dislikes to any of the foods served during the study.

Minimum Eligible Age

20 Years

Maximum Eligible Age

50 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes